Extract named element(s) from list(s) into long-format data frame
Source:R/utils.R
dfListExtractKey.Rd
(Deprecated, use dfTrials2Long and dfName2Value!) The function uses a name (key) to extract an element from a list in a data.frame such as obtained with dbGetFieldsIntoDf. This helps to simplify working with nested lists and with complex structures.
Arguments
- df
A data frame (or tibble)
- list.key
A list of pairs of list names and key names, where the list name corresponds to the name of a column in
df
that holds a list and the name of the key identifies the element to be extracted. See example.
Value
A data frame (or tibble, if dplyr
is loaded)
in long format with columns
name (identifying the full path in the data frame,
"<list>.<key>"), _id (of the trial record), value
(of name per _id), item (number of value of name
per _id).
Examples
dbc <- nodbi::src_sqlite(
dbname = system.file("extdata", "demo.sqlite", package = "ctrdata"),
collection = "my_trials")
df <- dbGetFieldsIntoDf(
fields = c(
"endPoints.endPoint",
"subjectDisposition.postAssignmentPeriods"),
con = dbc)
#> endPoints.endPoint...
#>
#> .
#>
#> subjectDisposition.postAssignmentPeriods...
#>
#> .
suppressWarnings(
dfListExtractKey(
df = df,
list.key = list(
c("endPoints.endPoint",
"^title"),
c("subjectDisposition.postAssignmentPeriods",
"arms.arm.type.value"))
))
#> name _id
#> 1 endPoints.endPoint.title 2012-003632-23-AT
#> 2 endPoints.endPoint.title 2012-003632-23-AT
#> 3 endPoints.endPoint.title 2012-003632-23-AT
#> 4 endPoints.endPoint.title 2012-003632-23-AT
#> 5 endPoints.endPoint.title 2012-003632-23-AT
#> 6 endPoints.endPoint.title 2012-003632-23-AT
#> 7 endPoints.endPoint.title 2012-003632-23-AT
#> 8 endPoints.endPoint.title 2012-003632-23-AT
#> 9 endPoints.endPoint.title 2012-003632-23-CZ
#> 10 endPoints.endPoint.title 2012-003632-23-CZ
#> 11 endPoints.endPoint.title 2012-003632-23-CZ
#> 12 endPoints.endPoint.title 2012-003632-23-CZ
#> 13 endPoints.endPoint.title 2012-003632-23-CZ
#> 14 endPoints.endPoint.title 2012-003632-23-CZ
#> 15 endPoints.endPoint.title 2012-003632-23-CZ
#> 16 endPoints.endPoint.title 2012-003632-23-CZ
#> 17 endPoints.endPoint.title 2012-003632-23-DE
#> 18 endPoints.endPoint.title 2012-003632-23-DE
#> 19 endPoints.endPoint.title 2012-003632-23-DE
#> 20 endPoints.endPoint.title 2012-003632-23-DE
#> 21 endPoints.endPoint.title 2012-003632-23-DE
#> 22 endPoints.endPoint.title 2012-003632-23-DE
#> 23 endPoints.endPoint.title 2012-003632-23-DE
#> 24 endPoints.endPoint.title 2012-003632-23-DE
#> 25 endPoints.endPoint.title 2012-003632-23-ES
#> 26 endPoints.endPoint.title 2012-003632-23-ES
#> 27 endPoints.endPoint.title 2012-003632-23-ES
#> 28 endPoints.endPoint.title 2012-003632-23-ES
#> 29 endPoints.endPoint.title 2012-003632-23-ES
#> 30 endPoints.endPoint.title 2012-003632-23-ES
#> 31 endPoints.endPoint.title 2012-003632-23-ES
#> 32 endPoints.endPoint.title 2012-003632-23-ES
#> 33 endPoints.endPoint.title 2012-003632-23-GB
#> 34 endPoints.endPoint.title 2012-003632-23-GB
#> 35 endPoints.endPoint.title 2012-003632-23-GB
#> 36 endPoints.endPoint.title 2012-003632-23-GB
#> 37 endPoints.endPoint.title 2012-003632-23-GB
#> 38 endPoints.endPoint.title 2012-003632-23-GB
#> 39 endPoints.endPoint.title 2012-003632-23-GB
#> 40 endPoints.endPoint.title 2012-003632-23-GB
#> 41 endPoints.endPoint.title 2012-003632-23-IT
#> 42 endPoints.endPoint.title 2012-003632-23-IT
#> 43 endPoints.endPoint.title 2012-003632-23-IT
#> 44 endPoints.endPoint.title 2012-003632-23-IT
#> 45 endPoints.endPoint.title 2012-003632-23-IT
#> 46 endPoints.endPoint.title 2012-003632-23-IT
#> 47 endPoints.endPoint.title 2012-003632-23-IT
#> 48 endPoints.endPoint.title 2012-003632-23-IT
#> 49 endPoints.endPoint.title 2012-003632-23-SE
#> 50 endPoints.endPoint.title 2012-003632-23-SE
#> 51 endPoints.endPoint.title 2012-003632-23-SE
#> 52 endPoints.endPoint.title 2012-003632-23-SE
#> 53 endPoints.endPoint.title 2012-003632-23-SE
#> 54 endPoints.endPoint.title 2012-003632-23-SE
#> 55 endPoints.endPoint.title 2012-003632-23-SE
#> 56 endPoints.endPoint.title 2012-003632-23-SE
#> 57 endPoints.endPoint.title 2013-005512-10-DE
#> 58 endPoints.endPoint.title 2013-005512-10-DE
#> 59 endPoints.endPoint.title 2013-005512-10-DE
#> 60 endPoints.endPoint.title 2013-005512-10-DE
#> 61 endPoints.endPoint.title 2013-005512-10-DE
#> 62 endPoints.endPoint.title 2013-005512-10-DE
#> 63 endPoints.endPoint.title 2013-005512-10-DE
#> 64 endPoints.endPoint.title 2013-005512-10-DE
#> 65 endPoints.endPoint.title 2013-005512-10-DE
#> 66 endPoints.endPoint.title 2013-005512-10-DE
#> 67 endPoints.endPoint.title 2013-005512-10-DK
#> 68 endPoints.endPoint.title 2013-005512-10-DK
#> 69 endPoints.endPoint.title 2013-005512-10-DK
#> 70 endPoints.endPoint.title 2013-005512-10-DK
#> 71 endPoints.endPoint.title 2013-005512-10-DK
#> 72 endPoints.endPoint.title 2013-005512-10-DK
#> 73 endPoints.endPoint.title 2013-005512-10-DK
#> 74 endPoints.endPoint.title 2013-005512-10-DK
#> 75 endPoints.endPoint.title 2013-005512-10-DK
#> 76 endPoints.endPoint.title 2013-005512-10-DK
#> 77 endPoints.endPoint.title 2013-005512-10-ES
#> 78 endPoints.endPoint.title 2013-005512-10-ES
#> 79 endPoints.endPoint.title 2013-005512-10-ES
#> 80 endPoints.endPoint.title 2013-005512-10-ES
#> 81 endPoints.endPoint.title 2013-005512-10-ES
#> 82 endPoints.endPoint.title 2013-005512-10-ES
#> 83 endPoints.endPoint.title 2013-005512-10-ES
#> 84 endPoints.endPoint.title 2013-005512-10-ES
#> 85 endPoints.endPoint.title 2013-005512-10-ES
#> 86 endPoints.endPoint.title 2013-005512-10-ES
#> 87 endPoints.endPoint.title 2013-005512-10-FR
#> 88 endPoints.endPoint.title 2013-005512-10-FR
#> 89 endPoints.endPoint.title 2013-005512-10-FR
#> 90 endPoints.endPoint.title 2013-005512-10-FR
#> 91 endPoints.endPoint.title 2013-005512-10-FR
#> 92 endPoints.endPoint.title 2013-005512-10-FR
#> 93 endPoints.endPoint.title 2013-005512-10-FR
#> 94 endPoints.endPoint.title 2013-005512-10-FR
#> 95 endPoints.endPoint.title 2013-005512-10-FR
#> 96 endPoints.endPoint.title 2013-005512-10-FR
#> 97 endPoints.endPoint.title 2013-005512-10-GB
#> 98 endPoints.endPoint.title 2013-005512-10-GB
#> 99 endPoints.endPoint.title 2013-005512-10-GB
#> 100 endPoints.endPoint.title 2013-005512-10-GB
#> 101 endPoints.endPoint.title 2013-005512-10-GB
#> 102 endPoints.endPoint.title 2013-005512-10-GB
#> 103 endPoints.endPoint.title 2013-005512-10-GB
#> 104 endPoints.endPoint.title 2013-005512-10-GB
#> 105 endPoints.endPoint.title 2013-005512-10-GB
#> 106 endPoints.endPoint.title 2013-005512-10-GB
#> 107 endPoints.endPoint.title 2013-005512-10-IE
#> 108 endPoints.endPoint.title 2013-005512-10-IE
#> 109 endPoints.endPoint.title 2013-005512-10-IE
#> 110 endPoints.endPoint.title 2013-005512-10-IE
#> 111 endPoints.endPoint.title 2013-005512-10-IE
#> 112 endPoints.endPoint.title 2013-005512-10-IE
#> 113 endPoints.endPoint.title 2013-005512-10-IE
#> 114 endPoints.endPoint.title 2013-005512-10-IE
#> 115 endPoints.endPoint.title 2013-005512-10-IE
#> 116 endPoints.endPoint.title 2013-005512-10-IE
#> 117 endPoints.endPoint.title 2013-005512-10-IT
#> 118 endPoints.endPoint.title 2013-005512-10-IT
#> 119 endPoints.endPoint.title 2013-005512-10-IT
#> 120 endPoints.endPoint.title 2013-005512-10-IT
#> 121 endPoints.endPoint.title 2013-005512-10-IT
#> 122 endPoints.endPoint.title 2013-005512-10-IT
#> 123 endPoints.endPoint.title 2013-005512-10-IT
#> 124 endPoints.endPoint.title 2013-005512-10-IT
#> 125 endPoints.endPoint.title 2013-005512-10-IT
#> 126 endPoints.endPoint.title 2013-005512-10-IT
#> 127 endPoints.endPoint.title 2013-005512-10-NL
#> 128 endPoints.endPoint.title 2013-005512-10-NL
#> 129 endPoints.endPoint.title 2013-005512-10-NL
#> 130 endPoints.endPoint.title 2013-005512-10-NL
#> 131 endPoints.endPoint.title 2013-005512-10-NL
#> 132 endPoints.endPoint.title 2013-005512-10-NL
#> 133 endPoints.endPoint.title 2013-005512-10-NL
#> 134 endPoints.endPoint.title 2013-005512-10-NL
#> 135 endPoints.endPoint.title 2013-005512-10-NL
#> 136 endPoints.endPoint.title 2013-005512-10-NL
#> 137 endPoints.endPoint.title 2013-005512-10-PL
#> 138 endPoints.endPoint.title 2013-005512-10-PL
#> 139 endPoints.endPoint.title 2013-005512-10-PL
#> 140 endPoints.endPoint.title 2013-005512-10-PL
#> 141 endPoints.endPoint.title 2013-005512-10-PL
#> 142 endPoints.endPoint.title 2013-005512-10-PL
#> 143 endPoints.endPoint.title 2013-005512-10-PL
#> 144 endPoints.endPoint.title 2013-005512-10-PL
#> 145 endPoints.endPoint.title 2013-005512-10-PL
#> 146 endPoints.endPoint.title 2013-005512-10-PL
#> 147 endPoints.endPoint.title 2013-005512-10-SE
#> 148 endPoints.endPoint.title 2013-005512-10-SE
#> 149 endPoints.endPoint.title 2013-005512-10-SE
#> 150 endPoints.endPoint.title 2013-005512-10-SE
#> 151 endPoints.endPoint.title 2013-005512-10-SE
#> 152 endPoints.endPoint.title 2013-005512-10-SE
#> 153 endPoints.endPoint.title 2013-005512-10-SE
#> 154 endPoints.endPoint.title 2013-005512-10-SE
#> 155 endPoints.endPoint.title 2013-005512-10-SE
#> 156 endPoints.endPoint.title 2013-005512-10-SE
#> 157 endPoints.endPoint.title 2014-003556-31-GB
#> 158 endPoints.endPoint.title 2014-003556-31-GB
#> 159 endPoints.endPoint.title 2014-003556-31-GB
#> 160 endPoints.endPoint.title 2014-003556-31-GB
#> 161 endPoints.endPoint.title 2014-003556-31-GB
#> 162 endPoints.endPoint.title 2014-003556-31-GB
#> 163 endPoints.endPoint.title 2014-003556-31-GB
#> 164 endPoints.endPoint.title 2014-003556-31-GB
#> 165 endPoints.endPoint.title 2014-003556-31-GB
#> 166 endPoints.endPoint.title 2014-003556-31-GB
#> 167 endPoints.endPoint.title 2014-003556-31-GB
#> 168 endPoints.endPoint.title 2014-003556-31-GB
#> 169 endPoints.endPoint.title 2014-003556-31-GB
#> 170 endPoints.endPoint.title 2014-003556-31-GB
#> 171 endPoints.endPoint.title 2014-003556-31-GB
#> 172 endPoints.endPoint.title 2014-003556-31-GB
#> 173 endPoints.endPoint.title 2014-003556-31-GB
#> 174 endPoints.endPoint.title 2014-003556-31-GB
#> 175 endPoints.endPoint.title 2014-003556-31-GB
#> 176 endPoints.endPoint.title 2014-003556-31-GB
#> 177 endPoints.endPoint.title 2014-003556-31-GB
#> 178 endPoints.endPoint.title 2014-003556-31-GB
#> 179 endPoints.endPoint.title 2014-003556-31-GB
#> 180 endPoints.endPoint.title 2014-003556-31-GB
#> 181 endPoints.endPoint.title 2014-003556-31-GB
#> 182 endPoints.endPoint.title 2014-003556-31-GB
#> 183 endPoints.endPoint.title 2014-003556-31-GB
#> 184 endPoints.endPoint.title 2014-003556-31-GB
#> 185 endPoints.endPoint.title 2014-003556-31-GB
#> 186 endPoints.endPoint.title 2014-003556-31-GB
#> 187 endPoints.endPoint.title 2014-003556-31-GB
#> 188 endPoints.endPoint.title 2014-003556-31-GB
#> 189 endPoints.endPoint.title 2014-003556-31-GB
#> 190 endPoints.endPoint.title 2014-003556-31-GB
#> 191 endPoints.endPoint.title 2014-003556-31-GB
#> 192 endPoints.endPoint.title 2014-003556-31-GB
#> 193 endPoints.endPoint.title 2014-003556-31-GB
#> 194 endPoints.endPoint.title 2014-003556-31-GB
#> 195 endPoints.endPoint.title 2014-003556-31-GB
#> 196 endPoints.endPoint.title 2014-003556-31-GB
#> 197 endPoints.endPoint.title 2014-003556-31-IT
#> 198 endPoints.endPoint.title 2014-003556-31-IT
#> 199 endPoints.endPoint.title 2014-003556-31-IT
#> 200 endPoints.endPoint.title 2014-003556-31-IT
#> 201 endPoints.endPoint.title 2014-003556-31-IT
#> 202 endPoints.endPoint.title 2014-003556-31-IT
#> 203 endPoints.endPoint.title 2014-003556-31-IT
#> 204 endPoints.endPoint.title 2014-003556-31-IT
#> 205 endPoints.endPoint.title 2014-003556-31-IT
#> 206 endPoints.endPoint.title 2014-003556-31-IT
#> 207 endPoints.endPoint.title 2014-003556-31-IT
#> 208 endPoints.endPoint.title 2014-003556-31-IT
#> 209 endPoints.endPoint.title 2014-003556-31-IT
#> 210 endPoints.endPoint.title 2014-003556-31-IT
#> 211 endPoints.endPoint.title 2014-003556-31-IT
#> 212 endPoints.endPoint.title 2014-003556-31-IT
#> 213 endPoints.endPoint.title 2014-003556-31-IT
#> 214 endPoints.endPoint.title 2014-003556-31-IT
#> 215 endPoints.endPoint.title 2014-003556-31-IT
#> 216 endPoints.endPoint.title 2014-003556-31-IT
#> 217 endPoints.endPoint.title 2014-003556-31-IT
#> 218 endPoints.endPoint.title 2014-003556-31-IT
#> 219 endPoints.endPoint.title 2014-003556-31-IT
#> 220 endPoints.endPoint.title 2014-003556-31-IT
#> 221 endPoints.endPoint.title 2014-003556-31-IT
#> 222 endPoints.endPoint.title 2014-003556-31-IT
#> 223 endPoints.endPoint.title 2014-003556-31-IT
#> 224 endPoints.endPoint.title 2014-003556-31-IT
#> 225 endPoints.endPoint.title 2014-003556-31-IT
#> 226 endPoints.endPoint.title 2014-003556-31-IT
#> 227 endPoints.endPoint.title 2014-003556-31-IT
#> 228 endPoints.endPoint.title 2014-003556-31-IT
#> 229 endPoints.endPoint.title 2014-003556-31-IT
#> 230 endPoints.endPoint.title 2014-003556-31-IT
#> 231 endPoints.endPoint.title 2014-003556-31-IT
#> 232 endPoints.endPoint.title 2014-003556-31-IT
#> 233 endPoints.endPoint.title 2014-003556-31-IT
#> 234 endPoints.endPoint.title 2014-003556-31-IT
#> 235 endPoints.endPoint.title 2014-003556-31-IT
#> 236 endPoints.endPoint.title 2014-003556-31-IT
#> 237 endPoints.endPoint.title 2014-003556-31-NL
#> 238 endPoints.endPoint.title 2014-003556-31-NL
#> 239 endPoints.endPoint.title 2014-003556-31-NL
#> 240 endPoints.endPoint.title 2014-003556-31-NL
#> 241 endPoints.endPoint.title 2014-003556-31-NL
#> 242 endPoints.endPoint.title 2014-003556-31-NL
#> 243 endPoints.endPoint.title 2014-003556-31-NL
#> 244 endPoints.endPoint.title 2014-003556-31-NL
#> 245 endPoints.endPoint.title 2014-003556-31-NL
#> 246 endPoints.endPoint.title 2014-003556-31-NL
#> 247 endPoints.endPoint.title 2014-003556-31-NL
#> 248 endPoints.endPoint.title 2014-003556-31-NL
#> 249 endPoints.endPoint.title 2014-003556-31-NL
#> 250 endPoints.endPoint.title 2014-003556-31-NL
#> value
#> 1 Time to Overall Response
#> 2 Durability of First Response
#> 3 Glucocortoid Tapering
#> 4 Survival Pre-HSCT
#> 5 Overall Survival
#> 6 Overall Response
#> 7 Survival Post-HSCT
#> 8 Cumulative Duration of Response
#> 9 Time to Overall Response
#> 10 Durability of First Response
#> 11 Glucocortoid Tapering
#> 12 Survival Pre-HSCT
#> 13 Overall Survival
#> 14 Overall Response
#> 15 Survival Post-HSCT
#> 16 Cumulative Duration of Response
#> 17 Time to Overall Response
#> 18 Durability of First Response
#> 19 Glucocortoid Tapering
#> 20 Survival Pre-HSCT
#> 21 Overall Survival
#> 22 Overall Response
#> 23 Survival Post-HSCT
#> 24 Cumulative Duration of Response
#> 25 Time to Overall Response
#> 26 Durability of First Response
#> 27 Glucocortoid Tapering
#> 28 Survival Pre-HSCT
#> 29 Overall Survival
#> 30 Overall Response
#> 31 Survival Post-HSCT
#> 32 Cumulative Duration of Response
#> 33 Time to Overall Response
#> 34 Durability of First Response
#> 35 Glucocortoid Tapering
#> 36 Survival Pre-HSCT
#> 37 Overall Survival
#> 38 Overall Response
#> 39 Survival Post-HSCT
#> 40 Cumulative Duration of Response
#> 41 Time to Overall Response
#> 42 Durability of First Response
#> 43 Glucocortoid Tapering
#> 44 Survival Pre-HSCT
#> 45 Overall Survival
#> 46 Overall Response
#> 47 Survival Post-HSCT
#> 48 Cumulative Duration of Response
#> 49 Time to Overall Response
#> 50 Durability of First Response
#> 51 Glucocortoid Tapering
#> 52 Survival Pre-HSCT
#> 53 Overall Survival
#> 54 Overall Response
#> 55 Survival Post-HSCT
#> 56 Cumulative Duration of Response
#> 57 Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 58 Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 59 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 60 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 61 Total Number of Exposure Days (EDs)
#> 62 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 63 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 64 Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 65 Change From Baseline in rFVIIIFc Incremental Recovery
#> 66 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 67 Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 68 Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 69 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 70 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 71 Total Number of Exposure Days (EDs)
#> 72 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 73 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 74 Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 75 Change From Baseline in rFVIIIFc Incremental Recovery
#> 76 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 77 Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 78 Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 79 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 80 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 81 Total Number of Exposure Days (EDs)
#> 82 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 83 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 84 Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 85 Change From Baseline in rFVIIIFc Incremental Recovery
#> 86 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 87 Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 88 Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 89 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 90 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 91 Total Number of Exposure Days (EDs)
#> 92 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 93 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 94 Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 95 Change From Baseline in rFVIIIFc Incremental Recovery
#> 96 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 97 Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 98 Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 99 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 100 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 101 Total Number of Exposure Days (EDs)
#> 102 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 103 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 104 Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 105 Change From Baseline in rFVIIIFc Incremental Recovery
#> 106 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 107 Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 108 Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 109 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 110 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 111 Total Number of Exposure Days (EDs)
#> 112 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 113 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 114 Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 115 Change From Baseline in rFVIIIFc Incremental Recovery
#> 116 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 117 Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 118 Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 119 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 120 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 121 Total Number of Exposure Days (EDs)
#> 122 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 123 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 124 Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 125 Change From Baseline in rFVIIIFc Incremental Recovery
#> 126 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 127 Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 128 Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 129 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 130 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 131 Total Number of Exposure Days (EDs)
#> 132 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 133 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 134 Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 135 Change From Baseline in rFVIIIFc Incremental Recovery
#> 136 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 137 Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 138 Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 139 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 140 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 141 Total Number of Exposure Days (EDs)
#> 142 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 143 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 144 Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 145 Change From Baseline in rFVIIIFc Incremental Recovery
#> 146 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 147 Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 148 Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 149 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 150 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 151 Total Number of Exposure Days (EDs)
#> 152 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 153 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 154 Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 155 Change From Baseline in rFVIIIFc Incremental Recovery
#> 156 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 157 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected age (CA)
#> 158 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 12 Months CA
#> 159 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 20 Months CA
#> 160 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 24 Months CA
#> 161 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 4.75 Years CA
#> 162 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 5 Years CA
#> 163 Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 12 Months CA
#> 164 Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 24 Months CA
#> 165 Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 5-Years CA
#> 166 Number of Participants With Nystagmus at 12 Months CA
#> 167 Number of Participants With Nystagmus at 24 Months CA
#> 168 Number of Participants With Nystagmus at 5 Years CA
#> 169 Refraction With Cycloplegia as Assessed by Retinoscopy at 6 Months CA
#> 170 Refraction With Cycloplegia as Assessed by Retinoscopy at 12 Month CA
#> 171 Refraction With Cycloplegia as Assessed by Retinoscopy at 20 Month CA
#> 172 Refraction With Cycloplegia as Assessed by Retinoscopy at 4.75 Years CA
#> 173 Number of Participants With Stereoacuity as Assessed With the Lang Stereotest At 5 Years CA
#> 174 Number of Participants With Adverse Events (AEs)
#> 175 Change From Baseline in Body Weight Z-score
#> 176 Change From Baseline in Height Z-score
#> 177 Change From Baseline in Head Circumference Z-score
#> 178 Change from Baseline (12 Months CA) in Cognitive Development as Assessed by Bayley Scales of Infant and Toddler Development (BSID-III) Composite Scores at 24 Months CA
#> 179 Cognitive Development as Assessed by Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV) Full Scale at 5 Years CA
#> 180 Number of Participants With Abnormal Physical Examination
#> 181 Number of Participants Diagnosed With Cerebral Palsy (CP) by Neurological Examination at 24 Months CA
#> 182 Change From Baseline (6 Months CA) in Child Behavior as Assessed by Vineland Adaptive Behaviour Scales (VABS-II)
#> 183 Number of Participants With Normal and Abnormal Hearing Screening Status
#> 184 Number of Participants With Child Behaviour as Assessed by Child Behaviour Checklist (CBCL) Based on T-Score Clinical Categories
#> 185 Child Behavior as Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS) Based on Total Score
#> 186 Number of Participants With Pulmonary Morbidity
#> 187 Child Behavior as Assessed by Social Communication Questionnaire (SCQ) Based on Total Score
#> 188 Number of Participants With Survival Status
#> 189 Change From Baseline (3 Months CA) in Pediatric Quality of Life Inventory (PedsQL™) Scale: Infant Scale
#> 190 Change From Baseline (24 Months CA) in Pediatric Quality of Life Inventory (PedsQL™) Scale: Generic Core Scale (GCS) Total Score
#> 191 Number of Participants With Health Status Measured by the Health Status Classification System-Preschool (HSCS-PS)
#> 192 Health Status Measured by the Health Utilities Index (HUI) Mark 2 and 3
#> 193 Health Care Resource Use (HCRU)
#> 194 Health Care Resource Utilization (HCRU): Number of Visits to Emergency Department
#> 195 Health Care Resource Utilization (HCRU): Duration of Hospitalization
#> 196 Health Care Resource Utilization (HCRU): Number of Participants who Required Prescription Eyeglasses and Educational Support
#> 197 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected age (CA)
#> 198 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 12 Months CA
#> 199 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 20 Months CA
#> 200 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 24 Months CA
#> 201 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 4.75 Years CA
#> 202 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 5 Years CA
#> 203 Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 12 Months CA
#> 204 Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 24 Months CA
#> 205 Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 5-Years CA
#> 206 Number of Participants With Nystagmus at 12 Months CA
#> 207 Number of Participants With Nystagmus at 24 Months CA
#> 208 Number of Participants With Nystagmus at 5 Years CA
#> 209 Refraction With Cycloplegia as Assessed by Retinoscopy at 6 Months CA
#> 210 Refraction With Cycloplegia as Assessed by Retinoscopy at 12 Month CA
#> 211 Refraction With Cycloplegia as Assessed by Retinoscopy at 20 Month CA
#> 212 Refraction With Cycloplegia as Assessed by Retinoscopy at 4.75 Years CA
#> 213 Number of Participants With Stereoacuity as Assessed With the Lang Stereotest At 5 Years CA
#> 214 Number of Participants With Adverse Events (AEs)
#> 215 Change From Baseline in Body Weight Z-score
#> 216 Change From Baseline in Height Z-score
#> 217 Change From Baseline in Head Circumference Z-score
#> 218 Change from Baseline (12 Months CA) in Cognitive Development as Assessed by Bayley Scales of Infant and Toddler Development (BSID-III) Composite Scores at 24 Months CA
#> 219 Cognitive Development as Assessed by Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV) Full Scale at 5 Years CA
#> 220 Number of Participants With Abnormal Physical Examination
#> 221 Number of Participants Diagnosed With Cerebral Palsy (CP) by Neurological Examination at 24 Months CA
#> 222 Change From Baseline (6 Months CA) in Child Behavior as Assessed by Vineland Adaptive Behaviour Scales (VABS-II)
#> 223 Number of Participants With Normal and Abnormal Hearing Screening Status
#> 224 Number of Participants With Child Behaviour as Assessed by Child Behaviour Checklist (CBCL) Based on T-Score Clinical Categories
#> 225 Child Behavior as Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS) Based on Total Score
#> 226 Number of Participants With Pulmonary Morbidity
#> 227 Child Behavior as Assessed by Social Communication Questionnaire (SCQ) Based on Total Score
#> 228 Number of Participants With Survival Status
#> 229 Change From Baseline (3 Months CA) in Pediatric Quality of Life Inventory (PedsQL™) Scale: Infant Scale
#> 230 Change From Baseline (24 Months CA) in Pediatric Quality of Life Inventory (PedsQL™) Scale: Generic Core Scale (GCS) Total Score
#> 231 Number of Participants With Health Status Measured by the Health Status Classification System-Preschool (HSCS-PS)
#> 232 Health Status Measured by the Health Utilities Index (HUI) Mark 2 and 3
#> 233 Health Care Resource Use (HCRU)
#> 234 Health Care Resource Utilization (HCRU): Number of Visits to Emergency Department
#> 235 Health Care Resource Utilization (HCRU): Duration of Hospitalization
#> 236 Health Care Resource Utilization (HCRU): Number of Participants who Required Prescription Eyeglasses and Educational Support
#> 237 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected age (CA)
#> 238 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 12 Months CA
#> 239 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 20 Months CA
#> 240 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 24 Months CA
#> 241 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 4.75 Years CA
#> 242 Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 5 Years CA
#> 243 Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 12 Months CA
#> 244 Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 24 Months CA
#> 245 Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 5-Years CA
#> 246 Number of Participants With Nystagmus at 12 Months CA
#> 247 Number of Participants With Nystagmus at 24 Months CA
#> 248 Number of Participants With Nystagmus at 5 Years CA
#> 249 Refraction With Cycloplegia as Assessed by Retinoscopy at 6 Months CA
#> 250 Refraction With Cycloplegia as Assessed by Retinoscopy at 12 Month CA
#> item
#> 1 1
#> 2 2
#> 3 3
#> 4 4
#> 5 5
#> 6 6
#> 7 7
#> 8 8
#> 9 1
#> 10 2
#> 11 3
#> 12 4
#> 13 5
#> 14 6
#> 15 7
#> 16 8
#> 17 1
#> 18 2
#> 19 3
#> 20 4
#> 21 5
#> 22 6
#> 23 7
#> 24 8
#> 25 1
#> 26 2
#> 27 3
#> 28 4
#> 29 5
#> 30 6
#> 31 7
#> 32 8
#> 33 1
#> 34 2
#> 35 3
#> 36 4
#> 37 5
#> 38 6
#> 39 7
#> 40 8
#> 41 1
#> 42 2
#> 43 3
#> 44 4
#> 45 5
#> 46 6
#> 47 7
#> 48 8
#> 49 1
#> 50 2
#> 51 3
#> 52 4
#> 53 5
#> 54 6
#> 55 7
#> 56 8
#> 57 1
#> 58 2
#> 59 3
#> 60 4
#> 61 5
#> 62 6
#> 63 7
#> 64 8
#> 65 9
#> 66 10
#> 67 1
#> 68 2
#> 69 3
#> 70 4
#> 71 5
#> 72 6
#> 73 7
#> 74 8
#> 75 9
#> 76 10
#> 77 1
#> 78 2
#> 79 3
#> 80 4
#> 81 5
#> 82 6
#> 83 7
#> 84 8
#> 85 9
#> 86 10
#> 87 1
#> 88 2
#> 89 3
#> 90 4
#> 91 5
#> 92 6
#> 93 7
#> 94 8
#> 95 9
#> 96 10
#> 97 1
#> 98 2
#> 99 3
#> 100 4
#> 101 5
#> 102 6
#> 103 7
#> 104 8
#> 105 9
#> 106 10
#> 107 1
#> 108 2
#> 109 3
#> 110 4
#> 111 5
#> 112 6
#> 113 7
#> 114 8
#> 115 9
#> 116 10
#> 117 1
#> 118 2
#> 119 3
#> 120 4
#> 121 5
#> 122 6
#> 123 7
#> 124 8
#> 125 9
#> 126 10
#> 127 1
#> 128 2
#> 129 3
#> 130 4
#> 131 5
#> 132 6
#> 133 7
#> 134 8
#> 135 9
#> 136 10
#> 137 1
#> 138 2
#> 139 3
#> 140 4
#> 141 5
#> 142 6
#> 143 7
#> 144 8
#> 145 9
#> 146 10
#> 147 1
#> 148 2
#> 149 3
#> 150 4
#> 151 5
#> 152 6
#> 153 7
#> 154 8
#> 155 9
#> 156 10
#> 157 1
#> 158 2
#> 159 3
#> 160 4
#> 161 5
#> 162 6
#> 163 7
#> 164 8
#> 165 9
#> 166 10
#> 167 11
#> 168 12
#> 169 13
#> 170 14
#> 171 15
#> 172 16
#> 173 17
#> 174 18
#> 175 19
#> 176 20
#> 177 21
#> 178 22
#> 179 23
#> 180 24
#> 181 25
#> 182 26
#> 183 27
#> 184 28
#> 185 29
#> 186 30
#> 187 31
#> 188 32
#> 189 33
#> 190 34
#> 191 35
#> 192 36
#> 193 37
#> 194 38
#> 195 39
#> 196 40
#> 197 1
#> 198 2
#> 199 3
#> 200 4
#> 201 5
#> 202 6
#> 203 7
#> 204 8
#> 205 9
#> 206 10
#> 207 11
#> 208 12
#> 209 13
#> 210 14
#> 211 15
#> 212 16
#> 213 17
#> 214 18
#> 215 19
#> 216 20
#> 217 21
#> 218 22
#> 219 23
#> 220 24
#> 221 25
#> 222 26
#> 223 27
#> 224 28
#> 225 29
#> 226 30
#> 227 31
#> 228 32
#> 229 33
#> 230 34
#> 231 35
#> 232 36
#> 233 37
#> 234 38
#> 235 39
#> 236 40
#> 237 1
#> 238 2
#> 239 3
#> 240 4
#> 241 5
#> 242 6
#> 243 7
#> 244 8
#> 245 9
#> 246 10
#> 247 11
#> 248 12
#> 249 13
#> 250 14
#> [ reached 'max' / getOption("max.print") -- omitted 143 rows ]